Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Double Blind, Sponsor Open, Randomized, Placebo And Active Comparator Controlled, Dose Escalation Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Escalating Doses Of Pf-05251749 In Healthy Adult And Elderly Subjects

NCT02691702 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT02691702
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02691702 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Double Blind, Sponsor Open, Randomized, Placebo And Active Comparator Controlled, Dose Escalation Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Escalating Doses Of Pf-05251749 In Healthy Adult And Elderly Subjects
Lead sponsor
Biogen
Phase
Phase 1
Overall status
Completed
Start date
March 28, 2016
Completion date
January 12, 2017
Enrollment
97 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

healthy adult subjects, healthy elderly subjects